By Judy George, Deputy Managing Editor, MedPage Today
September 18, 2026
In a landmark decision for the rare disease community, the U.S. Food and Drug Administration (FDA) has officially granted approval to rebisufligene etisparvovec—marketed under the brand name Fayuvi—as the first-ever treatment for pediatric patients diagnosed with mucopolysaccharidosis type IIIA (MPS IIIA), colloquially known as Sanfilippo syndrome type A.
This historic authorization marks a turning point in the management of an ultra-rare, fatal genetic condition that has historically offered parents nothing but palliative care. For families living under the shadow of a diagnosis that is often described as "childhood dementia," Fayuvi offers a flicker of hope where there was previously none.
Understanding the Clinical Landscape: What is MPS IIIA?
Mucopolysaccharidosis type IIIA is a devastating lysosomal storage disorder. It is triggered by a deficiency in the sulfamidase (SGSH) enzyme. In healthy individuals, this enzyme is responsible for breaking down complex sugar molecules known as heparan sulfate. However, in patients with MPS IIIA, the absence of this enzyme leads to the toxic accumulation of heparan sulfate within cells.
The consequences are catastrophic, particularly for the central nervous system. As the waste products build up, they trigger rapid, progressive neurodegeneration. Typically, children appear healthy at birth, only to begin experiencing global developmental delays in early childhood. This is followed by a relentless regression of cognitive, language, and motor skills. By the time many children reach their teenage years, they have lost the ability to speak, walk, or perform basic daily functions. With a median life expectancy of just 15 years, the condition is one of the most aggressive and heart-wrenching neurodegenerative diseases in pediatrics.
The Mechanism of Action: How Fayuvi Works
Rebisufligene etisparvovec represents the cutting edge of precision medicine. It is a one-time, intravenous gene therapy that utilizes an adeno-associated virus serotype 9 (AAV9) vector. The viral vector acts as a sophisticated delivery vehicle, carrying a functional copy of the SGSH gene into the patient’s cells.
Once inside the body, the therapy enables the patient’s own cells to produce the missing sulfamidase enzyme. By restoring this enzymatic activity, the body can effectively break down heparan sulfate, preventing its toxic buildup in the brain and peripheral tissues. The goal is to stabilize or potentially preserve neurological function before irreversible damage occurs.
"Achieving meaningful neurodevelopmental benefit through a single intravenous administration represents a significant scientific milestone," said Megha Kaushal, MD, MSc, acting deputy director of the FDA’s Office of Therapeutic Products. "It demonstrates that systemic AAV9-mediated gene delivery can reach the central nervous system at therapeutically relevant levels in pediatric patients, a hurdle that has long challenged gene therapy researchers."
Chronology of Development: From Rejection to Approval
The road to approval for Fayuvi has been fraught with both scientific triumph and regulatory turbulence.
- The Early Trials: Ultragenyx Pharmaceutical, the developer of the therapy, spent years conducting open-label, single-arm, multicenter clinical trials to prove the safety and efficacy of the gene therapy.
- The Regulatory Setback: In 2025, the journey hit a major obstacle when the FDA issued a Complete Response Letter (CRL) rejecting the treatment. At that time, the agency cited specific manufacturing concerns rather than a lack of clinical efficacy. This forced Ultragenyx to pause, refine its production processes, and engage in extensive dialogue with federal regulators to satisfy safety and quality standards.
- The Final Push: After addressing the manufacturing deficiencies and providing additional data, the company resubmitted its application. The FDA’s decision this Thursday serves as a validation of the company’s efforts to ensure that the complex, high-stakes manufacturing of a gene therapy could meet the rigorous consistency requirements of the FDA.
Supporting Data: Clinical Efficacy and Safety
The FDA’s approval was based on compelling evidence from clinical studies measuring mean changes in cognitive scores among patients aged 2 to 5 years. In the study, children who received a single dose of rebisufligene etisparvovec demonstrated a maintenance or improvement in cognitive function compared to an untreated historical control cohort—a stark difference for a disease characterized by inevitable decline.
However, the therapy is not without significant risk. As with any potent biological agent, safety remains paramount.
Common Adverse Reactions
The most frequently reported side effects across clinical trials included:
- Elevated liver enzymes (transaminase elevations)
- Nausea and vomiting
- Pyrexia (fever)
- Decreased appetite
- Hematologic abnormalities, specifically decreased white blood cell and platelet counts
- Increased amylase levels
The "Black Box" of Gene Therapy
The FDA has included specific safety warnings regarding the potential for thrombotic microangiopathy (TMA). Furthermore, the agency has issued a precautionary warning regarding the long-term risks inherent to all AAV-based gene therapies: the possibility that the inserted genetic material could integrate into the host genome. While this integration is designed to be stable, there is a theoretical risk that such integration could lead to tumor development over the course of a patient’s lifetime.
Economic Implications and Access
The arrival of Fayuvi is not only a medical milestone but an economic one. Ultragenyx has announced a U.S. list price of $3.95 million for the one-time therapy. While this price tag is staggering, it aligns with the high costs associated with the development, manufacturing, and long-term monitoring of gene therapies for ultra-rare conditions.
The debate surrounding the cost of gene therapy continues to intensify. With the potential to transform a fatal diagnosis into a manageable condition, the value proposition for families and insurers is significant, yet the budgetary impact on healthcare systems remains a subject of intense scrutiny. For parents of children with MPS IIIA, the primary concern is not the price tag, but the timeline for access. As of this week, the healthcare community is beginning the complex process of integrating this therapy into specialized treatment centers across the country.
Future Implications for Neurological Disorders
The success of rebisufligene etisparvovec has implications that extend far beyond MPS IIIA. It provides a proof-of-concept for treating other lysosomal storage disorders and neurodegenerative conditions that have previously been considered "untreatable."
The ability of the AAV9 vector to cross the blood-brain barrier and deliver therapeutic genes directly to the central nervous system is a technological breakthrough. If this delivery method can be scaled and refined, it could pave the way for treatments targeting diseases such as Tay-Sachs, Krabbe disease, and various forms of leukodystrophy.
For now, the focus remains on the children. The FDA has approved Fayuvi specifically for patients with preserved neurodevelopmental function, highlighting the necessity of early diagnosis and intervention. Newborn screening programs and increased physician awareness will be critical in ensuring that children are identified early enough to benefit from this life-altering gene therapy.
As the medical community digests this news, the mood is one of cautious optimism. While Fayuvi is not a "cure-all" and carries inherent risks, it represents the first time that medicine has been able to directly intervene in the genetic mechanism of Sanfilippo syndrome. For the families who have waited years for this day, the approval of rebisufligene etisparvovec is the most significant development in the history of their fight against this cruel, silent thief of childhood.
